当前位置: 首页 > 期刊 > 《中国医药科学》 > 2017年第9期
编号:13090020
吉西他滨联合替吉奥对比吉西他滨单药三线治疗晚期非小细胞肺癌的疗效及安全性(4)
http://www.100md.com 2017年10月8日 《中国医药科学》 2017年第9期
     [11] Okamoto I, Yoshioka H, Morita S, et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-na?ve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study[J].J ClinOncol,2010,28 (36):5240-5246.

    [12] Kubota K, Sakai H, Katakami NAnn Oncol. A randomized phase III trial of oralS-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial[J].2015 ,26(7):1401-1408.

    [13] 孫殿选.吉西他滨联合顺铂方案治疗晚期非小细胞肺癌36例临床分析[J].哈尔滨医药,2014,34(3):99-100.

    [14] Pressacco J, Wiley JS, Jamieson GP, et al. Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis[J]. Br J Cancer,1995,72:939 -942.

    [15] Takiguchi Y,Seto T,Ichinose Y,et al.Long-termadministration of second-linechemotherapy with S-1 and gemcitabine for platinum-resistantnon-small cell lung cancer: a phase II study[J]. J Thorac Oncol,2011,6(1):156-160.

    [16] 张杰,徐可,王少龙.吉西他滨联合替吉奥二线治疗老年IIIB 期肺鳞癌的疗效观察[J].临床肿瘤学杂志,2016,21(6):530-534.

    (收稿日期:2017-04-17), 百拇医药(冯卫能?张华?陈泽程?唐溢聪?梁剑苗?冼海兵?邓燕明)
上一页1 2 3 4